NEW YORK (GenomeWeb News) – Cancer genomics firm Foundation Medicine has filed to go public, with a target goal of raising as much as $86.3 million.

The Cambridge, Mass.-based firm has not yet priced its shares or said how many shares it plans to offer in its initial public offering. It plans to list on the Nasdaq under ticker symbol "FMI".

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.